

Final - June 22-23, 2022

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 22-23, 2022

	<u>AGENDA ITEM</u>	<u>PRESIDER/PRESENTER(S)</u>
Wednesday, June 22, 2022		
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:30	Influenza Vaccine Introduction Vaccine effectiveness update Influenza vaccination of older adults Summary, work group considerations, and proposed 2022-23 recommendations	Dr. Keipp Talbot (ACIP, WG Chair) Dr. Jessie Chung (CDC/NCIRD) Dr. Lisa Grohskopf (CDC/NCIRD) Dr. Lisa Grohskopf (CDC/NCIRD)
12:25	Break	
12:35	Pneumococcal Vaccines Introduction PCV15 Pediatric Clinical Development Program – Update Economic analysis and public health Impact of PCV15 use in children Summary of WG interpretation on EtR Proposed recommendations for PCV15 use in children	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Natalie Banniettis (Merck) Dr. Andrew Leidner (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD)
2:05	Break	
2:15	Measles, Mumps, and Rubella (MMR) Vaccine Introduction EtR and proposed recommendations	Ms. Lynn Bahta (ACIP, WG Chair) Dr. Elisabeth Krow-Lucal (CDC/NCIRD)
2:55	Break	
3:00	Public Comment	
3:20	Votes Influenza Vaccine Pneumococcal Vaccines Pneumococcal Vaccines - VFC vote MMR Vaccine	Dr. Lisa Grohskopf (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD) Dr. Elisabeth Krow-Lucal (CDC/NCIRD)
4:20	Break	
4:30	Human Papillomavirus (HPV) Vaccine National and state-level HPV vaccination coverage Impact of the US HPV vaccination program on HPV-associated outcomes One-dose HPV vaccination – overview of current evidence	Dr. Shannon Stokley (CDC/NCIRD) Dr. Julia Gargano (CDC/NCIRD) Dr. Lauri Markowitz (CDC/NCIRD)
5:10	Adjourn	
Thursday, June 23, 2022		
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:15	Agency Updates	
10:30	Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Burden, prevalence and trends of long-term sequelae of SARS-CoV-2 Updates on safety of COVID-19 vaccines in children and adolescents VaST assessment Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy in children and adolescents ages 6-17 years Evidence to Recommendation Framework: Moderna COVID-19 vaccine in children and adolescents ages 6-17 years Clinical Considerations update	Dr. Matthew Daley (ACIP, WG Chair) Dr. Melissa Briggs-Hagen (CDC/NCIRD) Dr. Tom Shimabukuro (CDC/NCEZID) Dr. Keipp Talbot (ACIP, VaST Chair) Dr. Rituparna Das (Moderna) Dr. Sara Oliver (CDC/NCIRD) Dr. Elisha Hall (CDC/NCIRD)
1:00	Discussion	
1:10	Public Comment	
1:30	Vote(s) Moderna COVID-19 vaccine in children ages 6-17 years	Dr. Sara Oliver (CDC/NCIRD)

Final - June 22-23, 2022

1:50		Break	
1:55	Meningococcal Vaccines		
	Introduction		Dr. Kathy Poehling (ACIP, WG Chair)
2:00	Respiratory Syncytial Virus (RSV) Vaccine		
	Introduction		Dr. Camille Kotton (ACIP, WG Chair)
	RSV virion & vaccine products		Dr. Natalie Thornburg (CDC/NCIRD)
	Epidemiology of RSV in children		Dr. Meredith McMorrow (CDC/NCIRD)
	Epidemiology of RSV in adults		Dr. Fiona Havers (CDC/NCIRD)
	Safety and efficacy of Nirsevimab in infants		Dr. Christian Felter (Sanofi)
3:30		Break	
3:40	Chikungunya Vaccines		
	Introduction		Dr. Beth Bell (ACIP, WG Chair)
	Overview of chikungunya and chikungunya vaccines		Dr. Susan Hills (CDC/NCEZID)
	Plans and timeline for work group activities		Dr. Susan Hills (CDC/NCEZID)
4:15	Monkeypox Informational Session		
	Situational update		Dr. Agam Rao (CDC/NCEZID)
	Medical countermeasures		Dr. Brett Petersen (CDC/NCEZID)
5:00	Adjourn		

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
MMR	Measles, Mumps, and Rubella Vaccine
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
PCV15	15-valent Pneumococcal Conjugate Vaccine
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness